Monica Cepin, MD
General Practice · Chula Vista, CANPI 1083795124
Payments from drug & device makers
Across 433 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AstraZeneca$843
- Lilly USA, LLC$838
- Johnson & Johnson$829
- Novo Nordisk$752
- AbbVie$537
- plus $4K from 33 others
What the payments were for
- Food & beverage$9,69999%
- Education$1011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 73 | $1,886 |
| AstraZeneca | 42 | $843 |
| Lilly USA, LLC | 41 | $838 |
| Johnson & Johnson | 50 | $829 |
| Novo Nordisk | 31 | $752 |
| AbbVie(2 entities) | 28 | $537 |
| Abbott | 6 | $419 |
| Bayer | 13 | $397 |
| Sanofi-aventis U.S. LLC | 15 | $306 |
| Boehringer Ingelheim | 18 | $278 |
| GSK | 12 | $258 |
| Merck | 13 | $252 |
| Medtronic(2 entities) | 5 | $225 |
| Novartis | 11 | $217 |
| Astellas Pharma US Inc | 9 | $204 |
| Boston Scientific | 2 | $176 |
| Amarin Pharma, Inc. | 8 | $175 |
| Dexcom, Inc. | 7 | $166 |
| Sunovion Pharmaceuticals Inc. | 8 | $133 |
| Radius Health, Inc. | 5 | $124 |
| Pfizer | 6 | $111 |
| Alnylam Pharmaceuticals Inc. | 1 | $109 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $81 |
| Biohaven Pharmaceuticals, Inc. | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $50 |
| Xeris Pharmaceuticals, Inc. | 2 | $46 |
| IBSA Pharma Inc. | 2 | $40 |
| Acadia Pharmaceuticals Inc | 1 | $40 |
| Shield Therapeutics Inc | 1 | $35 |
| Eisai Inc. | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Cequr Corporation | 2 | $26 |
| Exact Sciences | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Seqirus USA Inc | 1 | $18 |
| Valeritas, Inc. | 1 | $17 |
| Mycovia Pharmaceuticals, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Quadra Assura CRT Defibrillator$181
- AVEIR$159
- XARELTO$124
- Ozempic$122
- Repatha$122
- KRYSTEXXA$121
- RYBELSUS$118
- AMVUTTRA$109
- Kerendia$106
- LUX-Dx Insertable Cardiac Monitor$103
How this compares
$9,801 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 99 | $133,704 |
| JardianceEmpagliflozin | 101 | $81,425 |
| TrulicityDulaglutide | 64 | $74,358 |
| FarxigaDapagliflozin Propanediol | 65 | $39,304 |
| EliquisApixaban | 34 | $39,285 |
| JanumetSitagliptin Phos/Metformin Hcl | 37 | $37,594 |
| ProliaDenosumab | 20 | $33,184 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $22,075 |
| JanuviaSitagliptin Phosphate | 14 | $19,297 |
| XareltoRivaroxaban | 17 | $16,206 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $13,978 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 25 | $13,891 |
| TradjentaLinagliptin | 15 | $11,083 |
| LinzessLinaclotide | 15 | $10,046 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $9,618 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $752 | $133,70499 claims |
| Boehringer IngelheimJardiance, Tradjenta | $278 | $92,509116 claims |
| Lilly USA, LLCTrulicity | $838 | $74,35864 claims |
| MerckJanumet, Januvia, Janumet Xr | $252 | $70,78276 claims |
| AstraZenecaFarxiga | $843 | $39,30465 claims |
| PfizerEliquis | $111 | $39,28534 claims |
| AmgenProlia | $1,886 | $33,18420 claims |
| Johnson & JohnsonXarelto | $829 | $16,20617 claims |
| AbbVieLinzess, Synthroid | $537 | $11,33627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.
Other general practice in Chula Vista
- Sam HalaboChula Vista$359K
- Uri GuefenChula Vista$79K
- Hessam AazamiCanoga Park$88.4M
- Frederic MollRedwood City$5.7M
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Bruce TorkanLos Angeles$3.8M
- Daniel JohnsonPalm Desert$1.5M
- Bradley ChingUpland$1.4M
- Jared AdamsSan Francisco$862K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.